Advances in the etiology and pathogenesis of senile depression

doi:10.3877/cma.j.issn.2095-8757.2018.02.009

Abstract

Abstract:

Depression in the elderly is a complex mental disease. The influencing factors includes negative life events, age, gender, physical illness, economic status, personal vulnerability, social support, etc. The brain background constituted by these factors is more susceptible to the influence of stress, leading to pathological changes in the physiological structure, such as brain structural changes, vascular injury, inflammatory mechanisms, neuroendocrine changes, etc. This peper aims to review the recent advances in the etiology and pathogenesis of senile depression in order to provide reference for clinical treatment and prevention of depression in the elderly.

Key words: Aged, Depression, Pathogenesis, Research progress

Yao Yao, Yuan Gao. Advances in the etiology and pathogenesis of senile depression[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2018, 05(02): 45-49.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlnbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8757.2018.02.009

https://zhlnbyjdzzz.cma-cmc.com.cn/EN/Y2018/V05/I02/45

References 52

[1]	Charlton RA,Lamar M,Zhang A, et al. White-matter tract integrity in late-life depression: associations with severity and cognition[J].Psychol Med, 2014, 44(7):1427-1437.
[2]	Mitchell AJ,Rao S,Vaze A. Do primary care physicians have particular difficulty identifying late-life depression? A meta-analysis stratified by age[J]. Psychother Psychosom, 2010, 79(5):285-294.
[3]	Hickie IB,Naismith SL,Ward PB, et al. Serotonin transporter gene status predicts caudate nucleus but not amygdala or hippocampal volumes in older persons with major depression[J]. J Afferct Disord, 2007, 98(1-2):137-142.
[4]	Alexopoulos GS,Murphy CF,Gunningdixon FM, et al. Serotonin transporter polymorphisms, microstructural white matter abnormalities and remission of geriatric depression[J]. J Afferct Disord, 2009, 119(3):132-141.
[5]	Taylor WD,Steffens DC,Payne ME, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression[J]. Arch Gen Psychiatry, 2005, 62(5):537.
[6]	Duman RS,Monteggia LM. A neurotrophic model for stress-related mood disorders[J]. Biol Psychiatry, 2006, 59(12):1116-1127.
[7]	Berton O,Mcclung CA,Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress[J]. Science, 2006, 311(5762):864-868.
[8]	Pei Y,Smith AK,Wang Y, et al. The brain-derivedneurotrophic-factor (BDNF) val66met polymorphism is associated with geriatric depression: a meta-analysis[J]. Am J Med Genet B Neuropsychiatr Genet, 2012, 159B(5):560-566.
[9]	Kanellopoulos D,Gunning FM,Morimoto SS, et al. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression[J]. Am J Geriatr Psychiatry, 2011, 19(1):13-22.
[10]	Taylor WD,Züchner S,Mcquoid DR, et al. Allelic differences in the brain-derived neurotrophic factor Val66Met polymorphism in late-life depression[J]. Am J Geriatr Psychiatry, 2007, 15(10):850-857.
[11]	Kang HJ,Bae KY,Kim SW, et al. Longitudinal associations between glucocorticoid receptor methylation and late-life depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2018, 84(Pt A):56-62.
[12]	Andreescu C,Butters MA,Begley A, et al. Gray matterchanges in late life depression-a structural MRI analysis[J]. Neuropsychopharmacology, 2008, 33(11):2566.
[13]	Sexton CE,Allan CL,Le MM, et al. Magnetic resonance imaging in late-life depression: multimodal examination of network disruption[J]. Arch Gen Psychiatry, 2012, 69(7):680-689.
[14]	Smagula SF,Aizenstein HJ. Brain structural connectivity in late-life major depressive disorder[J]. Biol Psychiatry Cogn Neurosci Neuroimaging, 2016, 1(3):271-277.
[15]	Du M,Liu J,Chen Z, et al. Brain grey matter volume alterations in late-life depression[J]. J Psychiatry Neurosci, 2014, 39(6):397.
[16]	Charlton RA,Leow A,Gadelkarim J, et al. Brain connectivity in late-life depression and aging revealed by network analysis[J]. Am J Geriatr Psychiatry, 2015, 23(6):642.
[17]	Reppermund S,Zhuang L,Wen W, et al. White matter integrity and late-life depression in community-dwelling individuals: diffusion tensor imaging study using tract-based spatial statistics[J]. Br J Psychiatry, 2011, 205(4):315-320.
[18]	Guo W,Liu F,Xun G, et al. Disrupted white matter integrity in first-episode, drug-naive, late-onset depression[J]. J Affect Disord, 2014, 163(9):70-75.
[19]	Sin ELL,Liu HL,Lee SH, et al. The relationships between brain structural changes and perceived loneliness in older adults suffering from late‐life depression[J]. Int J Geriatr Psychiatry, 2018, 33(4):606-612.
[20]	Dubois B,Defontaines B,Deweer B, et al. Cognitive and behavioral changes in patients with focal lesions of the basal ganglia[J]. Adv Neurol, 1995, 65:29-41.
[21]	Bae JN,Macfall JR,Krishnan KR, et al. Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression[J]. Bio Psychiatry, 2006, 60(12):1356-1363.
[22]	Disabato BM,Morris C,Hranilovich J, et al. Comparison of brain structural variables, neuropsychological factors, and treatment outcome in early-onset versus late-onset late-life depression[J]. Am J Geriatr Psychiatry, 2013, 22(10):1039-1046.
[23]	Delaloye C,Moy G,De BF, et al. Neuroanatomical andneuropsychological features of elderly euthymic depressed patients with early-and late-onset[J]. J Neurol Sci, 2010, 299(1):19-23.
[24]	Andreescu C,Butters MA,Begley A, et al. Gray matterchanges in late life depression-a structural MRI analysis[J]. Neuropsychopharmacology, 2007, 33(11):2566.
[25]	Ballmaier M,Narr KL,Toga AW, et al. Hippocampal morphology and distinguishing late-onset from early-onset elderly depression[J]. Am J Psychiatry, 2008, 165(2):229-237.
[26]	Scott R,Paulson D. Cerebrovascular burden and depressive symptomatologyinterrelate over 18 years: support for the vascular depression hypothesis[J]. Int J Geriatr Psychiatry, 2017, 33(1):66-74.
[27]	Alexopoulos GS,Meyers S,Young RC, et al. 'Vascular depression' hypothesis[J]. Arch Gen Psychiatry, 1997, 54(10):915-922.
[28]	Greenstein AS,Paranthaman RA,Jackson A, et al. Cerebrovascular damage in late-life depression is associated with structural and functional abnormalities of subcutaneous small arteries[J]. Hypertension, 2010, 56(4):734.
[29]	Paranthaman R,Greenstein AS,Burns AS, et al. Vascular function in older adults with depressive disorder[J]. Bio Psychiatry, 2010, 68(2):133-139.
[30]	Tiemeier H,Breteler MM,van Popele NM, et al. Late-life depression is associated with arterial stiffness: a population-based study.[J]. J Am Geriatri Soc, 2010, 51(8):1105-1110.
[31]	Debiec J,Ledoux JE,Nader K. Cellular and systems reconsolidation in the hippocampus[J]. Neuron, 2002, 36(3):527-538.
[32]	Vardi N,Freedman N,Lester H, et al. Hyperintensities on T2-weighted images in the basal ganglia of patients with major depression: cerebral perfusion and clinical implications[J]. Psychiatry Res, 2011, 192(2):125-130.
[33]	Alexopoulos GS. Frontostriatal and limbic dysfunction in late-life depression[J]. Am J Geriatr Psychiatry, 2002, 10(6):687-695.
[34]	Maes M,Leonard BE,Myint AM, et al. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35(3):702-721.
[35]	Miller AH. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface[J].Brain Behav Immun, 2009, 23(2):149-158.
[36]	Tsao CW,Lin YS,Chen CC, et al. Cytokines and serotonin transporter in patients with major depression[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2006, 30(5):899-905.
[37]	Koo JW,Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress[J]. Proc Natl Acad Sci USA, 2008, 105(2):751-756.
[38]	Slavich GM,Way BM,Eisenberger NI, et al. Neural sensitivity to social rejection is associated with inflammatory responses to social stress[J]. Proc Natl Acad Sci USA, 2010, 107(33):14817-14822.
[39]	Harrison NA,Brydon L,Walker C, et al. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity[J]. Bio Psychiatry, 2009, 66(5):407-414.
[40]	Elderkin-Thompson V,Irwin MR,Hellemann G, et al. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults[J]. Am J Geriatr Psychiatry, 2012, 20(9):753-763.
[41]	Satizabal CL,Zhu YC,Mazoyer B, et al. Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-Dijon Study[J]. Neurology, 2012, 78(10):720-727.
[42]	Rhebergen D,Korten NC,Penninx BW, et al. Hypothalamic-pituitary-adrenal axis activity in older persons with and without a depressive disorder[J]. Psychoneuroendocrinology, 2015, 51:341-350.
[43]	Belvederi MM,Pariante C,Mondelli V, et al. HPA axis and aging in depression: systematic review and meta-analysis[J]. Psychoneuroendocrinology, 2014, 41(1):46-62.
[44]	Bahls SC,de Carvalho GA. [The relation between thyroid function and depression: a review][J]. Rev Bras Psiquiatr, 2004, 26(1):41-49.
[45]	Chueire VB,Romaldini JH,Ward LS. Subclinical hypothyroidism increases the risk for depression in the elderly[J]. Arc Gerontol Geriatri, 2007, 44(1):21-28.
[46]	Jr MG,Kremer C,Rodrigues HE, et al. Pharmacogenetics of antidepressant medication intolerance[J]. Am J Psychiatry, 2003, 160(10):1830-1835.
[47]	Sanacora G,Zarate CA,Krystal JH, et al. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders[J]. Nat Rev Drug Discov, 2008, 7(5):426-437.
[48]	Sanacora G,Mason GF,Rothman DL, et al. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors[J]. Am J Psychiatry, 2002, 159(4):663-665.
[49]	Silver AA,Shytle RD,Sheehan KH, et al. Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder[J]. J Am Acad Child Adolesc Psychiatry, 2001, 40(9):1103-1110.
[50]	Mathew SJ,Manji HK,Charney DS. Novel drugs and therapeutic targets for severe mood disorders[J]. Neuropsychopharmacology, 2008, 33(9):2080-2092.
[51]	Lanni C,Govoni S,Lucchelli A, et al. Depression and antidepressants: molecular and cellular aspects[J]. Cell Mol Life Sci, 2009, 66(18):2985-3008.
[52]	Herpfer I,Lieb K. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential[J].CNS Drugs, 2005, 19(4):275-293.

Please choose a citation manager

Content to export